

## 3-Amino-1-(4-methoxyphenyl)-9,10-dihydrophenanthrene-2,4-dicarbonitrile

**Abdullah M. Asiri,<sup>a,b</sup>‡ Abdulrahman O. Al-Youbi,<sup>a</sup> Hassan M. Faidallah,<sup>a</sup> Seik Weng Ng<sup>c</sup> and Edward R. T. Tiekkink<sup>c\*</sup>**

<sup>a</sup>Chemistry Department, Faculty of Science, King Abdulaziz University, PO Box 80203, Jeddah, Saudi Arabia, <sup>b</sup>The Center of Excellence for Advanced Materials Research, King Abdulaziz University, PO Box 80203, Jeddah, Saudi Arabia, and <sup>c</sup>Department of Chemistry, University of Malaya, 50603 Kuala Lumpur, Malaysia  
Correspondence e-mail: edward.tiekkink@gmail.com


Received 17 August 2011; accepted 18 August 2011

Key indicators: single-crystal X-ray study;  $T = 100$  K; mean  $\sigma(\text{C}-\text{C}) = 0.002 \text{ \AA}$ ;  $R$  factor = 0.048;  $wR$  factor = 0.116; data-to-parameter ratio = 15.4.

In the title compound,  $C_{23}H_{17}N_3O$ , significant deviations from planarity are evidenced. This is quantified in the dihedral angles formed between the central amino-benzene ring and the benzene rings of the methoxybenzene [67.93 (8) $^\circ$ ] and 1,2-dihydronaphthalene [28.27 (8) $^\circ$ ] residues. In the crystal the amino-H atoms form hydrogen bonds to the methoxy-O atom and to one of the cyano-N atoms to generate a two-dimensional array with a zigzag topology that stacks along the (1  $\bar{1}$  1) plane.

### Related literature

For background to the biological activity of related compounds, see: Aly *et al.* (1991); Al-Saadi *et al.* (2005); Rostom *et al.* (2011). For ring conformational analysis, see: Cremer & Pople (1975). For a related structure, see: Asiri *et al.* (2011).



### Experimental

#### Crystal data

$C_{23}H_{17}N_3O$

$M_r = 351.40$

‡ Additional correspondence author, e-mail: aasiri2@kau.edu.sa.

Monoclinic,  $P2_1/c$   
 $a = 9.0212 (4) \text{ \AA}$   
 $b = 22.1475 (8) \text{ \AA}$   
 $c = 9.3114 (4) \text{ \AA}$   
 $\beta = 110.410 (5)^\circ$   
 $V = 1743.60 (12) \text{ \AA}^3$

$Z = 4$   
Mo  $K\alpha$  radiation  
 $\mu = 0.08 \text{ mm}^{-1}$   
 $T = 100 \text{ K}$   
 $0.25 \times 0.25 \times 0.05 \text{ mm}$

#### Data collection

Agilent Technologies SuperNova Dual diffractometer with Atlas detector  
Absorption correction: multi-scan (*CrysAlis PRO*; Agilent, 2010)  
 $T_{\min} = 0.714$ ,  $T_{\max} = 1.000$

8688 measured reflections  
3890 independent reflections  
2953 reflections with  $I > 2\sigma(I)$   
 $R_{\text{int}} = 0.030$

#### Refinement

$R[F^2 > 2\sigma(F^2)] = 0.048$   
 $wR(F^2) = 0.116$   
 $S = 1.04$   
3890 reflections  
252 parameters  
2 restraints

H atoms treated by a mixture of independent and constrained refinement  
 $\Delta\rho_{\max} = 0.33 \text{ e \AA}^{-3}$   
 $\Delta\rho_{\min} = -0.23 \text{ e \AA}^{-3}$

**Table 1**  
Hydrogen-bond geometry ( $\text{\AA}$ ,  $^\circ$ ).

$D-\text{H}\cdots A$	$D-\text{H}$	$\text{H}\cdots A$	$D\cdots A$	$D-\text{H}\cdots A$
N2—H1 $\cdots$ O1 <sup>i</sup>	0.89 (1)	2.21 (1)	3.0307 (19)	154 (2)
N2—H2 $\cdots$ N1 <sup>ii</sup>	0.88 (1)	2.33 (1)	3.115 (2)	149 (2)

Symmetry codes: (i)  $x - 1, -y + \frac{1}{2}, z - \frac{1}{2}$ ; (ii)  $-x - 1, -y, -z$ .

Data collection: *CrysAlis PRO* (Agilent, 2010); cell refinement: *CrysAlis PRO*; data reduction: *CrysAlis PRO*; program(s) used to solve structure: *SHELXS97* (Sheldrick, 2008); program(s) used to refine structure: *SHELXL97* (Sheldrick, 2008); molecular graphics: *ORTEP-3* (Farrugia, 1997) and *DIAMOND* (Brandenburg, 2006); software used to prepare material for publication: *publCIF* (Westrip, 2010).

The authors thank King Abdulaziz University and the University of Malaya for supporting this study.

Supplementary data and figures for this paper are available from the IUCr electronic archives (Reference: HG5084).

### References

- Agilent (2010). *CrysAlis PRO*. Agilent Technologies, Yarnton, Oxfordshire, England.
- Al-Saadi, S. M., Rostom, S. A. F. & Faid Allah, H. M. (2005). *Alexandria J. Pharm. Sci.*, **19**, 15–21.
- Aly, A. S., El-Ezabawy, S. R. & Abdel-Fattah, A. M. (1991). *Egypt. J. Pharm. Sci.*, **32**, 827–834.
- Asiri, A. M., Al-Youbi, A. O., Faidallah, H. M., Ng, S. W. & Tiekkink, E. R. T. (2011). *Acta Cryst. E67*, o2438.
- Brandenburg, K. (2006). *DIAMOND*. Crystal Impact GbR, Bonn, Germany.
- Cremer, D. & Pople, J. A. (1975). *J. Am. Chem. Soc.*, **97**, 1354–1358.
- Farrugia, L. J. (1997). *J. Appl. Cryst.*, **30**, 565.
- Rostom, S. A. F., Faidallah, S. M. & Al Saadi, M. S. (2011). *Med. Chem. Res.* DOI: 10.1007/s00044-010-9469-0.
- Sheldrick, G. M. (2008). *Acta Cryst. A64*, 112–122.
- Westrip, S. P. (2010). *J. Appl. Cryst.*, **43**, 920–925.